Recent Projects - Market Access Strategy

 Recent projects undertaken by the Bridgehead Market Access Strategy team include the following:

Psychiatry

• A global biopharmaceutical company in the process of developing their Phase III clinical study programme for a product used to treat the symptoms of attention deficit hyperactivity disorder (ADHD) asked Bridgehead to convene and facilitate a series of European payer advisory board meetings. These meetings covered payer attitudes towards the client’s clinical study programme and advice on the client’s Health Economics and Outcomes Research plans.  For further information

Epilepsy and primary immune deficiency

• A US-based medical device company was developing technology to deliver drugs through innovative delivery mechanisms and, in advance of commercialization, was exploring two lead clinical applications for its technology.  They approached Bridgehead to carry out a landscape assessment of the market access drivers for the epilepsy and primary immune deficiency  markets within the US where they were planning to target their technology.  For further information

Oncology

• The client required core value dossiers for two different oncological products.  The products were used in the treatment of two different indications in the field of chronic lymphocytic leukaemia (CLL) and the client wished to maintain and enhance the access position and price for the products for continued commercial success. For further information

Cardiovascular

• A global pharmaceutical company had a hypertension therapy whose revenue had been eroded since the introduction of a competing generic.  The client wanted to protect their current patient base and grow the therapy’s market share in the emerging markets.  As part of this work, the client asked Bridgehead to create a pricing and access toolkit for these countries, which was to serve as an easy-to-use guide for diagnosing market issues and identifying solutions.The client also wanted to understand additional tactics and strategies of innovative pricing and access solutions in these countries that had not surfaced in its research up-to-date. For further information

Oncology

• A global pharmaceutical and healthcare company had an oncology product in Phase II development for initial launch indications in Non-Hodgkin Lymphoma (NHL).  A market access landscape assessment was required.  Bridgehead provided a broad international understanding of the NHL market, healthcare systems in the USA, EU5 and Japan and associated market access issues.  For further information